MendesM. Cardiopulmonary Exercise Test in the Evaluation of Heart Transplant Candidates with Atrial Fibrillation. Arq. Bras. Cardiol. 2020;114(2):219-21.
Mendes,Miguel. Cardiopulmonary Exercise Test in the Evaluation of Heart Transplant Candidates with Atrial Fibrillation. Arq. Bras. Cardiol., v. 114, n. 2, p. 219-221, Feb. 2020.
Mendes,M. (2020). Cardiopulmonary Exercise Test in the Evaluation of Heart Transplant Candidates with Atrial Fibrillation. Arq. Bras. Cardiol.,114(2), 219-221.
Mendes,Miguel. Cardiopulmonary Exercise Test in the Evaluation of Heart Transplant Candidates with Atrial Fibrillation. Arq. Bras. Cardiol. [online]. 2020, vol. 114, n. 2, [cited 2025-09-08], pp.219-221. Available from: <https://abccardiol.org/en/short-editorial/cardiopulmonary-exercise-test-in-the-evaluation-of-heart-transplant-candidates-with-atrial-fibrillation/>. ISSN 0066-782X.
Figure 1
Dyslipidemia as a central element in atherosclerotic cardiovascular disease. ASCVD: atherosclerotic cardiovascular disease; LDL-C: low-density lipoprotein cholesterol. Limitations of statin-based therapy (non-exhaustive) include suboptimal LDL-C goal attainment, statin-associated adverse effects that may affect adherence, and potential drug interactions. Residual risk reflects the involvement of multiple underlying pathways.
